MAPT and Alzheimer disease: In conclusion, while brain connectivity measures are not yet widely adopted as primary endpoints in clinical trials for Alzheimer’s disease, preliminary studies have shown that FC changes often precede Aβ and tau pathology and may provide an earlier indication of disease progression.